Document is current
Any future updates will be listed below
-
Authors
Potashman, Michele H. https://orcid.org/0000-0001-7389-3354
Popoff, Evan https://orcid.org/0000-0002-3233-3147
Powell, Lauren C. https://orcid.org/0000-0002-4329-5166
Beiner, Melissa Wolfe
Mackenzie, Ainsley
Coric, Vlad
Subramony, Sub https://orcid.org/0000-0002-8052-9240
Synofzik, Matthis https://orcid.org/0000-0002-2280-7273
Schmahmann, Jeremy https://orcid.org/0000-0003-0706-5125
L’Italien, Gilbert https://orcid.org/0009-0009-5196-003X
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03701399 at ClinicalTrials.govDocuments that mention this clinical trial
Measurement Properties of the Friedreich Ataxia Rating Scale in Patients with Spinocerebellar Ataxia
https://doi.org/10.1007/s40120-024-00708-4
Video-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc Analysis
https://doi.org/10.1007/s40120-024-00625-6
-
Funding
Funding for this research was provided by:
Biohaven Pharmaceuticals, Inc
- License Information
-
More Information
Article History
Received: 13 November 2024
Accepted: 20 December 2024
First Online: 13 January 2025
Declarations
:
: Michele Potashman, Ainsley Mackenzie, Melissa Wolfe Beiner, Vlad Coric, and Gilbert L’Italien are employees of Biohaven Pharmaceuticals, Inc. Evan Popoff and Lauren Powell are employees of Broadstreet HEOR, which received funds from Biohaven Pharmaceuticals, Inc, for this work. Sub Subramony has received research support from the National Ataxia Foundation, Biohaven Pharmaceuticals, Inc, National Institutes of Health, US Food and Drug Administration, Muscular Dystrophy Association, Wyck Foundation, Friedreich’s Ataxia Research Alliance, Reata, PTC Therapeutics, Retrotope, Avidity Biosciences, Fulcrum Therapeutics, Reneo Pharma, and AavantiBio; and has served on scientific advisory boards for Reata, Avidity, and Dyne Therapeutics. Matthis Synofzik has received consultancy honoraria from Ionis, UCB, Prevail, Orphazyme, Servier, Reata, GenOrph, AviadoBio, Biohaven, Solaxa, Zevra, and Lilly. Jeremy Schmahmann consults for Biohaven Pharmaceuticals and is site PI for Biohaven Pharmaceuticals clinical trials NCT03701399, NCT02960893, and NCT03952806; receives royalties from Oxford University Press, Elsevier, MacKeith Press, and Springer; and is the inventor of the Brief Ataxia Rating Scale, Cerebellar Cognitive Affective/Schmahmann Syndrome Scale, the Patient-Reported Outcome Measure of Ataxia, and the Cerebellar Neuropsychiatry Rating Scale, which are licensed to the General Hospital Corporation. He is supported in part by the National Ataxia Foundation, the MINDLink Foundation, and the Raynor Cerebellum Project.
: Study 206 (BHV4157-206; NCT03701399) was a multisite study approved by a centralized independent Institutional Review Board (Institutional Review Board; Advarra, Columbia, MD, USA), with additional local Institutional Review Board approvals obtained where requested (per institute). The PROM-Ataxia study (MGH psychometric cohort) was approved by Mass General Brigham Human Research Committee Institutional Review Board (Somerville, MA, USA). Both studies were conducted in accordance with the 1964 Declaration of Helsinki.
